Regenxbio Inc (NASDAQ:RGNX)’s stock price reached a new 52-week low on Thursday . The company traded as low as $35.70 and last traded at $35.83, with a volume of 6700 shares. The stock had previously closed at $36.70.
A number of research firms have recently weighed in on RGNX. Morgan Stanley set a $84.00 price objective on shares of Regenxbio and gave the stock a “buy” rating in a research note on Monday, July 15th. Evercore ISI set a $79.00 price objective on shares of Regenxbio and gave the stock a “buy” rating in a research note on Wednesday, August 7th. Raymond James began coverage on shares of Regenxbio in a research note on Thursday, June 13th. They issued an “outperform” rating on the stock. BidaskClub lowered shares of Regenxbio from a “sell” rating to a “strong sell” rating in a research note on Thursday. Finally, Chardan Capital reiterated a “buy” rating and issued a $150.00 price objective (up previously from $145.00) on shares of Regenxbio in a research note on Tuesday, June 18th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $84.88.
The stock has a market cap of $1.35 billion, a P/E ratio of 15.18 and a beta of 0.71. The company has a current ratio of 14.58, a quick ratio of 14.58 and a debt-to-equity ratio of 0.01. The business’s 50-day simple moving average is $46.04.
Regenxbio (NASDAQ:RGNX) last released its quarterly earnings results on Wednesday, August 7th. The biotechnology company reported ($0.04) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.50) by $0.46. The company had revenue of $7.88 million for the quarter, compared to analyst estimates of $5.45 million. Regenxbio had a negative net margin of 88.57% and a negative return on equity of 15.39%. The firm’s revenue was down 80.3% on a year-over-year basis. During the same quarter last year, the business earned $0.30 earnings per share. On average, sell-side analysts forecast that Regenxbio Inc will post -2.51 EPS for the current fiscal year.
In other news, insider Kenneth T. Mills sold 15,000 shares of Regenxbio stock in a transaction dated Monday, May 20th. The shares were sold at an average price of $42.99, for a total value of $644,850.00. Following the sale, the insider now owns 261,000 shares in the company, valued at $11,220,390. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, SVP Patrick J. Christmas sold 5,000 shares of Regenxbio stock in a transaction dated Tuesday, June 18th. The shares were sold at an average price of $52.99, for a total transaction of $264,950.00. Following the completion of the sale, the senior vice president now owns 8,006 shares in the company, valued at approximately $424,237.94. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 73,000 shares of company stock worth $3,590,400. 13.80% of the stock is owned by company insiders.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Mckinley Capital Management LLC Delaware grew its position in shares of Regenxbio by 51.8% in the first quarter. Mckinley Capital Management LLC Delaware now owns 888 shares of the biotechnology company’s stock valued at $51,000 after purchasing an additional 303 shares during the period. Financial Gravity Wealth Inc. acquired a new stake in shares of Regenxbio in the first quarter valued at about $55,000. Berman Capital Advisors LLC grew its position in shares of Regenxbio by 41.6% in the second quarter. Berman Capital Advisors LLC now owns 1,133 shares of the biotechnology company’s stock valued at $58,000 after purchasing an additional 333 shares during the period. NEXT Financial Group Inc acquired a new stake in shares of Regenxbio in the second quarter valued at about $69,000. Finally, SG3 Management LLC acquired a new stake in shares of Regenxbio in the first quarter valued at about $115,000. Institutional investors and hedge funds own 80.76% of the company’s stock.
Regenxbio Company Profile (NASDAQ:RGNX)
REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform.
Featured Story: Exchange-Traded Funds (ETFs)
Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.